Printer Friendly

Peregrine Pharmaceuticals Awarded New United States Patent Further Strengthening Its Anti-Phospholipid Patent Portfolio.

Peregrine Pharmaceuticals, Inc. (Tustin, CA) reported the issuance of a United States patent that further strengthens the company's intellectual property leadership in the field of phospholipid-targeting agents for the treatment of life-threatening diseases. The new patent grants composition of matter claims that cover multiple formulations of phosphatidylethanolamine (PE)-binding agents attached to a wide variety of anti-viral agents. PE belongs to the aminophospholipid family that also includes phosphatidylserine (PS), the target for Peregrine's monoclonal antibody bavituximab that is in a clinical trial for hepatitis C virus (HCV) infection and in preclinical studies for HIV and other viral infections. This new patent follows issuance last year of broad methods patents covering use of PE-binding agents in anti-viral applications.

"Our anti-viral program has gained momentum over the past year with prestigious scientific publications and presentations, as well as the award of a major federal contract to Peregrine for the development of our anti-PS antibodies for biodefense applications," said Steven W. King, president and CEO of Peregrine. "Our growing patent estate in the closely related field of anti-PE binding agents should provide us with additional scientific and strategic options for leveraging our promising anti-viral assets."

The science underlying Peregrine's patents for anti-viral applications of PE-targeting agents was presented at a scientific conference last year by Dr. Melina Soares of the University of Texas Southwestern Medical Center(1). Dr. Soares presented data showing that similar to PS, the aminophospholipid PE is normally located on the inside of cell membranes, but becomes exposed on the external surface of enveloped viruses and virus-infected cells. Using a biotin-conjugated form of the drug duramycin, which binds to PE, Dr. Soares and her colleagues demonstrated that exposed PE could serve as a broad-spectrum target for anti-viral therapy.

"We are very pleased to receive this third patent for our anti-PE program, which adds to our leadership in the emerging field of aminophospholipid-targeting anti-viral agents," said Shelley Fussey, Ph.D., vice president of intellectual property at Peregrine. "This latest patent is the direct result of our ongoing research collaboration with leading researchers at UT Southwestern Medical Center who have been instrumental in establishing our position at the forefront of developing therapeutic agents that target phospholipids."

United States Patent 7,511,124, which issued on March 31, 2009, was granted to the University of Texas System and is exclusively licensed to Peregrine Pharmaceuticals.

Peregrine Pharmaceuticals is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara.

Peregrine Pharmaceuticals, Inc.

+1-714-508-7370

www.peregrineinc.com
COPYRIGHT 2009 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:BIOTECH Patent News
Date:Mar 1, 2009
Words:444
Previous Article:Repligen Licenses Patent Rights for Treatment of Bipolar Disorder.
Next Article:Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International.
Topics:


Related Articles
Lorus Therapeutics' intellectual property portfolio strengthened by cancer patent.
Eleventh United States patent issued for Esperion's peptide program.
Peregrine obtains tumor treatment patent.
Peregrine announces patent grant for angiogenesis therapy.
Peregrine licenses additional intellectual property for its anti-phospholipid therapy platform technology.
Peregrine extends its platform of anti-cancer technologies.
Peregrine's phospholipid-targeted antibodies fused wth cytokines reduce tumor growth.
Peregrine Pharmaceuticals Awarded Two New U.S. Patents Broadening Its Targeted Anti-Phospholipid Patent Portfolio - New Claims Cover Anti-Viral...
Peregrine Awarded Patents Broadening Targeted Anti-Phospholipid Patent Portfolio.
Peregrine Pharmaceuticals awarded broad new United States patent for vascular imaging applications of its PS-Targeting platform.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters